Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Nivolumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 226 Carcinoma, Non-Small-Cell Lung 191 Carcinoma, Renal Cell 127 Neoplasm Metastasis 88 Neoplasms 79 Squamous Cell Carcinoma of Head and Neck 71 Carcinoma, Hepatocellular 71 Colorectal Neoplasms 66 Lung Neoplasms 61 Stomach Neoplasms 49 Pancreatic Neoplasms 46 Carcinoma, Transitional Cell 39 Urinary Bladder Neoplasms 36 Breast Neoplasms 36 Hodgkin Disease 35 Ovarian Neoplasms 34 Head and Neck Neoplasms 34 Triple Negative Breast Neoplasms 30 Small Cell Lung Carcinoma 29 Sarcoma 29 Brain Neoplasms 28 Glioblastoma 27 Prostatic Neoplasms 26 Kidney Neoplasms 26 Recurrence 24 Multiple Myeloma 21 Esophageal Neoplasms 21 Uveal Melanoma 19 Uterine Cervical Neoplasms 19 Skin Neoplasms 19

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡